Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : BioNTech aims to develop mRNA-based malaria vaccine

07/26/2021 | 10:00am EDT

(Corrects mRNA description in paragraph 7 to pathogen from virus)

* Plans to start clinical trial by end of 2022

* Malaria kills over 400,000 young children per year

* BioNTech explores vaccine production in Africa

BERLIN, July 26 (Reuters) - BioNTech wants to build on its success in COVID-19 by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end on 2022, in an attempt to eradicate the mosquito-borne illness.

The Mainz, Germany-based company, which developed a COVID-19 vaccine with its partner Pfizer, said on Monday it is also exploring vaccine production in Africa as part of efforts to expand manufacturing capacity and increase global access.

"The response to the pandemic has shown that science and innovation can transform people's lives when all key stakeholders work together towards a common goal," said BioNTech Chief Executive and co-founder Ugur Sahin.

Scientists around the world have been working for decades to develop a vaccine to prevent malaria that infects millions of people every year and kills more than 400,000 - most of them babies and young children in the poorest parts of Africa.

The world's first and only licensed malaria vaccine, Mosquirix, was developed by GlaxoSmithKline over many years of clinical trial across several African countries, but is only around 30% effective.

Researchers at Oxford's Jenner Institute led by Adrian Hill, one of the lead scientists behind the Oxford-AstraZeneca COVID-19 vaccine, are also developing a potential new malaria vaccine that has shown promise in a year-long trial.

MRNA vaccines prompt the human body to make a protein that is part of the pathogen, triggering an immune response.

BioNTech said it will assess multiple vaccine candidates that target the circumsporozoite protein (CSP), as well as new antigens discovered in pre-clinical research and select the most promising for a clinical trial due to start by the end of 2022.

The company is also evaluating setting up mRNA vaccine production in Africa, either with partners or on its own, as part of efforts to scale up manufacturing capacity in low- and middle-income countries.

BioNTech did not disclose how the project would be funded, but said the World Health Organisation (WHO), European Commission and other organisations have offered their support to set up the necessary infrastructure.

BioNTech also plans to start a clinical trial to test a vaccine candidate for tuberculosis in 2022 and is working with partners to develop vaccines against nine different infectious diseases as well as for cancer. (Reporting by Caroline Copley; Editing by Bernadette Baum)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.64% 8664.2098 Delayed Quote.17.65%
GLAXOSMITHKLINE PLC -0.56% 1420.4 Delayed Quote.6.48%
All news about ASTRAZENECA PLC
07:12aASTRAZENECA : Science Committee appointment (Form 6-K)
06:52aASTRAZENECA : establishes new Sustainability Committee of the Board (Form 6-K)
06:29aANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US...
06:06aASTRAZENECA : Coronavirus - 40,000 Vaccines Administered in Private Pharmacies
05:41aASTRAZENECA : Covid to be like the common cold - one day, says vaccine co-designer
04:10aASTRAZENECA : Credit Suisse reiterates its Buy rating
03:27aASTRAZENECA : Takes Stake In UK's VaxEquity Under Long-Term Partnership
02:21aASTRAZENECA : invests in Imperial's self-amplifying RNA technology with eye on future drug..
02:12aASTRAZENECA : to discover and develop self-amplifying RNA therapeutics in new collaboratio..
09/22ASTRAZENECA : Japan doubles COVID-19 vaccine donation pledge to 60 mln doses
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 32,8x
Yield 2021 2,40%
Capitalization 182 B 182 B -
EV / Sales 2021 5,82x
EV / Sales 2022 4,72x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 117,33 $
Average target price 136,23 $
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC17.65%182 344
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291